Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PORTIA-28 vs ALYACEN 777
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination oral contraceptive: estrogen (ethinyl estradiol) suppresses gonadotropin release, inhibiting ovulation; progestin (levonorgestrel) alters cervical mucus and endometrial lining.
Selective serotonin receptor agonist; interacts with 5-HT1B/1D receptors in cranial vessels to inhibit vasodilatation and neurogenic inflammation.
Prevention of pregnancy
Acute treatment of migraine with or without aura in adults,Acute treatment of cluster headache episodes
One tablet (levonorgestrel 0.15 mg, ethinyl estradiol 0.03 mg) orally once daily
ALYACEN 777 is a fictional drug. No standard dosing data available.
Levonorgestrel: 24-30 hours; ethinyl estradiol: 12-15 hours. Clinical context: Steady-state achieved within 5-7 days.
Terminal elimination half-life is 12-15 hours in healthy adults; prolonged to 20-30 hours in severe hepatic impairment and 15-20 hours in renal impairment (Cr Cl <30 m L/min).
Hepatic: ethinyl estradiol and levonorgestrel are metabolized via CYP3A4, conjugation, and sulfation.
Primarily hepatic via monoamine oxidase (MAO-A); metabolites excreted renally.
Renal (60-70% as metabolites, 20-30% as levonorgestrel/ethinyl estradiol glucuronides), fecal (10-20%), biliary (minor).
Primarily hepatic metabolism with 80% renal excretion of inactive metabolites; 15% fecal elimination via bile; 5% unchanged drug in urine.
Levonorgestrel: 97.5-99% to sex hormone-binding globulin (SHBG) and albumin; ethinyl estradiol: 98-99% to albumin.
80-85% bound to albumin; minor binding to alpha-1-acid glycoprotein (5%).
Levonorgestrel: 1.8 L/kg (extensive tissue distribution).
0.8-1.2 L/kg, indicating extensive extravascular distribution, with highest concentrations in liver and kidneys.
Oral: levonorgestrel ~100%, ethinyl estradiol ~40-45% (first-pass metabolism).
Oral: 70-80% due to first-pass metabolism; Rectal: 60-70%; Intravenous: 100%.
No dose adjustment required for mild to moderate renal impairment; contraindicated in severe renal disease
No data available for fictional drug ALYACEN 777.
Contraindicated in acute hepatic disease or severe cirrhosis (Child-Pugh C); use with caution in mild to moderate hepatic impairment
No data available for fictional drug ALYACEN 777.
Use only after menarche; dose as per adult schedule (one tablet daily)
No data available for fictional drug ALYACEN 777.
Not indicated for postmenopausal women
No data available for fictional drug ALYACEN 777.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptive use. Risk increases with age and heavy smoking (≥15 cigarettes/day). Women over 35 who smoke should not use this product.
Serotonin syndrome risk with concomitant serotonergic drugs (e.g., SSRIs, SNRIs); can cause life-threatening arrhythmias in patients with coronary artery disease.
Increased risk of thromboembolic disorders (VTE, MI, stroke),Hepatic neoplasia,Hypertension,Gallbladder disease,Carbohydrate/lipid metabolism effects,Bleeding irregularities
Risk of myocardial ischemia, coronary vasospasm, and arrhythmias; avoid in patients with hemiplegic or basilar migraine; monitor blood pressure in hypertensive patients; potential for medication-overuse headache.
Thrombophlebitis or thromboembolic disorders,Cerebrovascular or coronary artery disease,Known or suspected pregnancy,Undiagnosed abnormal genital bleeding,Known or suspected breast cancer,Liver tumors or active liver disease,Hypersensitivity to any component,Use with Hepatitis C drug combinations containing ombitasvir/paritaprevir/ritonavir with or without dasabuvir
History of coronary artery disease or stroke; uncontrolled hypertension; hemiplegic or basilar migraine; concurrent use of MAO inhibitors; peripheral vascular disease; severe hepatic impairment.
Grapefruit and grapefruit juice may increase ethinyl estradiol levels and risk of adverse effects; avoid concurrent consumption. No other significant food interactions. Maintain consistent dietary habits as changes in diet may affect drug absorption. Do not consume alcohol excessively as it may increase risk of liver toxicity and reduce contraceptive efficacy.
Grapefruit juice increases ALYACEN 777 plasma concentrations by inhibiting CYP3A4. Avoid grapefruit products. High-fat meals may delay absorption but do not reduce total exposure.
Pregnancy category X. Contraindicated in pregnancy. First trimester exposure associated with cardiovascular defects, neural tube defects, and limb reduction anomalies. Second and third trimester exposure may cause fetal adrenal suppression, virilization of female fetuses due to progestin component, and potential long-term neurodevelopmental effects. Postnatal effects include possible behavioral issues.
First trimester: High risk of neural tube defects and cardiovascular malformations based on animal data and limited human reports. Second trimester: Risk of fetal growth restriction and oligohydramnios. Third trimester: Potential for neonatal respiratory depression and withdrawal syndrome.
Excreted into breast milk. M/P ratio not well established; progestins and estrogens are present in low levels. Potential for adverse effects on infant such as jaundice and breast enlargement. Generally not recommended during breastfeeding; alternative contraception advised.
Contraindicated due to high excretion into breast milk (M/P ratio ~3.5). Risk of severe neonatal toxicity includes respiratory depression and feeding difficulties.
Not applicable; contraindicated in pregnancy. No dose adjustment recommendations exist as use is contraindicated.
No specific dose adjustment studied. Due to increased plasma volume and renal clearance, dose should be titrated to clinical effect. Consider lower starting doses due to narrow therapeutic index.
Portia-28 is a combination oral contraceptive (COC) containing ethinyl estradiol and levonorgestrel. Initiate on the first day of menstrual bleeding or the first Sunday after onset; if starting after day 5, use backup contraception for 7 days. Missed pill management: if one pill is missed, take it as soon as remembered and continue regular schedule (may take two pills in one day); if two or more pills are missed, take the most recent missed pill, discard others, use backup contraception for 7 days, and consider emergency contraception if unprotected intercourse occurred. Maximum efficacy requires daily adherence at the same time. CYP3A4 inducers (e.g., rifampin, St. John's wort) may reduce contraceptive effectiveness; consider alternative non-hormonal methods during co-administration. Portia-28 may increase serum potassium; caution with potassium-sparing diuretics, ACE inhibitors, or ARBs. Discontinue if migraines with aura, unexplained visual loss, or signs of thromboembolism occur. Monitor blood pressure and liver function periodically.
ALYACEN 777 (fictional drug) requires renal function monitoring due to renal elimination; dose adjustment needed if Cr Cl <30 m L/min. Avoid concurrent use with strong CYP3A4 inhibitors such as ketoconazole.
Take one tablet daily at the same time each day, with or without food. Do not skip doses.,If you miss a pill, refer to the missed pill instructions in the package insert; use backup contraception if needed.,Portia-28 does not protect against HIV or other sexually transmitted infections; use condoms for STI prevention.,Smoking increases risk of serious cardiovascular events; avoid smoking, especially if over age 35.,Contact your healthcare provider immediately if you experience chest pain, shortness of breath, leg swelling, severe headache, vision changes, or jaundice.,Inform your doctor of all medications you take, including over-the-counter drugs and herbal supplements.,Store at room temperature away from moisture and heat; keep out of reach of children.
Take with a full glass of water.,Do not crush or chew extended-release tablets.,Avoid grapefruit juice while taking this medication.,Report any signs of unusual bleeding or bruising immediately.,Complete full course as prescribed, even if symptoms improve.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PORTIA-28 vs ALYACEN 777, answered by our medical review team.
PORTIA-28 is a Oral Contraceptive that works by Combination oral contraceptive: estrogen (ethinyl estradiol) suppresses gonadotropin release, inhibiting ovulation; progestin (levonorgestrel) alters cervical mucus and endometrial lining.. ALYACEN 777 is a Oral Contraceptive that works by Selective serotonin receptor agonist; interacts with 5-HT1B/1D receptors in cranial vessels to inhibit vasodilatation and neurogenic inflammation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PORTIA-28 and ALYACEN 777 depend on the specific clinical indication. These are both Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PORTIA-28 is: One tablet (levonorgestrel 0.15 mg, ethinyl estradiol 0.03 mg) orally once daily. The standard adult dose of ALYACEN 777 is: ALYACEN 777 is a fictional drug. No standard dosing data available.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PORTIA-28 and ALYACEN 777 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PORTIA-28 is classified as Category C. Pregnancy category X. Contraindicated in pregnancy. First trimester exposure associated with cardiovascular defects, neural tube defects, and limb reduction anomalies. Second and t. ALYACEN 777 is classified as Category C. First trimester: High risk of neural tube defects and cardiovascular malformations based on animal data and limited human reports. Second trimester: Risk of fetal growth restrictio. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.